DE69001503D1 - D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen. - Google Patents

D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.

Info

Publication number
DE69001503D1
DE69001503D1 DE9090104875T DE69001503T DE69001503D1 DE 69001503 D1 DE69001503 D1 DE 69001503D1 DE 9090104875 T DE9090104875 T DE 9090104875T DE 69001503 T DE69001503 T DE 69001503T DE 69001503 D1 DE69001503 D1 DE 69001503D1
Authority
DE
Germany
Prior art keywords
alanine
memory
cycloserin
improving
mixture containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE9090104875T
Other languages
English (en)
Other versions
DE69001503T2 (de
Inventor
Alexis A Cordi
Michael R Jans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69001503D1 publication Critical patent/DE69001503D1/de
Publication of DE69001503T2 publication Critical patent/DE69001503T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE9090104875T 1989-03-15 1990-03-15 D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen. Expired - Fee Related DE69001503T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
DE69001503D1 true DE69001503D1 (de) 1993-06-09
DE69001503T2 DE69001503T2 (de) 1993-09-09

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
DE9090104875T Expired - Fee Related DE69001503T2 (de) 1989-03-15 1990-03-15 D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.

Country Status (17)

Country Link
US (1) US5061721A (de)
EP (1) EP0387867B1 (de)
JP (1) JP2963720B2 (de)
KR (1) KR900013961A (de)
AT (1) ATE88890T1 (de)
AU (1) AU624917B2 (de)
CA (1) CA2010635C (de)
DE (1) DE69001503T2 (de)
DK (1) DK0387867T3 (de)
ES (1) ES2055197T3 (de)
FI (1) FI901289A0 (de)
GR (1) GR3008225T3 (de)
IE (1) IE64130B1 (de)
IL (1) IL93562A (de)
NO (1) NO901198L (de)
NZ (1) NZ232809A (de)
PT (1) PT93424B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
CA2159326C (en) * 1993-03-29 2000-05-30 Robert Kisilevsky Method for treating amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
US6172041B1 (en) 1996-07-22 2001-01-09 University Of Utah Research Foundation Use of conantokins
CA2601132C (en) * 1998-04-14 2011-11-08 The General Hospital Corporation Use of n-methylglycine and pharmaceutical compositions comprising n-methylglycine for treating neuropsychiatric disorders
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1383465B1 (de) * 2001-03-29 2011-08-10 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US7846913B2 (en) 2003-12-29 2010-12-07 Mcdevitt Jason Patrick Compositions and methods to treat recurrent medical conditions
WO2002078615A2 (en) * 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
JP2005527525A (ja) * 2002-03-15 2005-09-15 ハー・ルンドベック・アクチエゼルスカベット 神経学的及び精神医学的障害の治療にａｓｃ−１阻害剤を使用する方法
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1660634A4 (de) * 2003-08-08 2009-02-18 Burnham Inst P16-vermittelte regulation von nmda-rezeptoren
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
KR101406456B1 (ko) 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
JP5702288B2 (ja) 2008-09-18 2015-04-15 ノースウエスタン ユニバーシティ Ｎｍｄａレセプターモジュレータ及びその用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
ES2706063T3 (es) 2010-02-11 2019-03-27 Univ Northwestern Agonistas del receptor de NMDA y usos del mismo
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
ES2734405T3 (es) 2013-01-29 2019-12-05 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
MX2015009778A (es) 2013-01-29 2016-02-09 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
MX2019001318A (es) 2016-08-01 2019-07-01 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
EP3490992B1 (de) 2016-08-01 2023-03-22 Aptinyx Inc. Spöiro-lactam nmda rezeptor modulatoren und deren verwendung
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
NO901198L (no) 1990-09-17
EP0387867B1 (de) 1993-05-05
DE69001503T2 (de) 1993-09-09
ATE88890T1 (de) 1993-05-15
EP0387867A1 (de) 1990-09-19
CA2010635C (en) 2001-03-06
US5061721A (en) 1991-10-29
CA2010635A1 (en) 1990-09-15
JP2963720B2 (ja) 1999-10-18
AU5073490A (en) 1990-09-20
IE900921L (en) 1990-09-15
IL93562A (en) 1996-01-31
IL93562A0 (en) 1990-11-29
NZ232809A (en) 1992-05-26
IE64130B1 (en) 1995-07-12
FI901289A0 (fi) 1990-03-15
KR900013961A (ko) 1990-10-22
PT93424A (pt) 1990-11-07
NO901198D0 (no) 1990-03-14
GR3008225T3 (de) 1993-09-30
ES2055197T3 (es) 1994-08-16
DK0387867T3 (da) 1993-06-01
JPH03148221A (ja) 1991-06-25
AU624917B2 (en) 1992-06-25
PT93424B (pt) 1996-08-30

Similar Documents

Publication Publication Date Title
DE69001503D1 (de) D-cycloserin und d-alanin enthaltende mischung zur verbesserung des gedaechtnisses und des lernvermoegens oder zur behandlung von kognitiven und psychotischen erkrankungen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69426351T2 (de) Verfahren zur Modifizierung des Wachstums von Körperhaaren und/oder Haaren und hierfür verwendbare Zusammensetzungen
DE69204639T2 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
AU2883689A (en) The use of moclobemide to treat or prevent cognitive disorders
PH24568A (en) Use of bezafibrate for treating diabetes
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE68900917D1 (de) Behandlungsverfahren fuer zyanid und/oder sonstige oxidierbare stoffe enthaltenden abwaessern.
DE69305267D1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
DE59407415D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 8
DE58902451D1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
DE68902511D1 (de) Dermato-kosmetische zusammensetzung zur behandlung des hautalterns und zur verhuetung von falten.
ATE124727T1 (de) Verfahren zur behandlung von häuten und so erhaltene häute.
DE59407412D1 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha
ATE87614T1 (de) Methoden zur verwendung von 2-isopropyl-2phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ZA901995B (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee